MoonLake ImmunotherapeuticsMLTX
MLTX
About: MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Employees: 100
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
147% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 15
141% more call options, than puts
Call options by funds: $21.1M | Put options by funds: $8.78M
18% more funds holding
Funds holding: 115 [Q4 2024] → 136 (+21) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 6 [Q4 2024] → 6 (+0) [Q1 2025]
5.92% less ownership
Funds ownership: 100.57% [Q4 2024] → 94.65% (-5.92%) [Q1 2025]
28% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 43
32% less capital invested
Capital invested by funds: $3.43B [Q4 2024] → $2.34B (-$1.09B) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$61
38%
upside
Avg. target
$65
46%
upside
High target
$67
52%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Brian Abrahams | 52%upside $67 | Outperform Reiterated | 3 Jun 2025 |
Wolfe Research Andy Chen | 38%upside $61 | Outperform Upgraded | 19 May 2025 |
Needham Serge Belanger | 49%upside $66 | Buy Reiterated | 13 May 2025 |
Financial journalist opinion
Based on 4 articles about MLTX published over the past 30 days
Positive
Zacks Investment Research
1 week ago
MLTX Stock Gains 18% as Merck Reportedly Eyes Buyout
MoonLake jumps 18% after a report says MRK made a $3 billion-plus offer earlier this year, with talks potentially set to resume.
Positive
Seeking Alpha
1 week ago
MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest
MoonLake Immunotherapeutics completed enrollment of the two phase 3 VELA studies using Sonelokimab for the treatment of patients with hidradenitis suppurativa. The global psoriatic arthritis market is projected to reach $24.2 billion by the end of 2031. Merck's $3 billion non-binding acquisition offer highlights significant buyout potential of company and validates its late-stage pipeline value.
Positive
Investors Business Daily
1 week ago
MoonLake Immunotherapeutics Catapults On Rumored Merck Takeover
Biotech stock MoonLake Immunotherapeutics rocketed Tuesday on a report Merck offered to buy it for "more than $3 billion."
Positive
Reuters
1 week ago
Merck held talks to buy biotech MoonLake for over $3 billion, FT reports
Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported on Monday, citing three people familiar with the matter.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think MOONLAKE IMMUNO (MLTX) Could Surge 106.62%: Read This Before Placing a Bet
The consensus price target hints at a 106.6% upside potential for MOONLAKE IMMUNO (MLTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Neutral
GlobeNewsWire
1 month ago
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody ® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA) Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trial Presented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab in an indication with currently no approved therapeutics in the US and Europe, and further derisking the overall development of sonelokimab Ended the first quarter with $480.1 million in cash, cash equivalents and short-term marketable debt securities and announced closing of a debt facility, providing up to $500 million in non-dilutive funds and extending expected cash runway into 2028 ZUG, Switzerland, May 12, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced its financial results for the first quarter of 2025. Matthias Bodenstedt, Chief Financial Officer of MoonLake Immunotherapeutics, said: “We continue executing across our portfolio of indications with quality, speed and efficiency.
Neutral
GlobeNewsWire
1 month ago
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29
MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a virtual Capital Markets Day for investors and analysts on Tuesday, April 29, 2025. The event will highlight recent financial and clinical milestones and provide future strategic updates.
Positive
Seeking Alpha
2 months ago
MoonLake Immunotherapeutics: A Buy At Dips
MoonLake Immunotherapeutics showed strong performance with sonelokimab, outperforming competitors in clinical trials, yet faced a significant stock drop due to institutional sell-offs. Despite mixed results from the ARGO study, sonelokimab demonstrated superior efficacy against Humira and Secukinumab, indicating strong potential for future success. Institutional sell-offs in late 2023 caused a drastic stock decline, but MLTX remains financially stable with a cash runway extending into 2027.
Neutral
GlobeNewsWire
2 months ago
MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
Zug, Switzerland, April 3, 2025 – MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in customized debt financing for companies in the life sciences and technology-related markets, for up to $500 million in non-dilutive capital, of which $75 million drawn down at close and additional tranches will become available upon achievement of certain pre-specified milestones that are aligned with MoonLake's strategy and funding needs.
Neutral
GlobeNewsWire
3 months ago
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
ZUG, Switzerland, February 26, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced its financial results for the fourth quarter and year ended December 31, 2024.
Charts implemented using Lightweight Charts™